糖脂清治疗糖耐量减低合并脂代谢紊乱的临床研究
|
摘要
目的：探讨中医学对糖耐量减低合并脂代谢紊乱的认识,采用糖脂清方治疗糖耐量减低合并脂代谢紊乱气阴两虚,痰瘀壅阻证。通过随机对照临床试验,观察糖脂清方对糖耐量减低合并脂代谢紊乱气阴两虚,痰瘀壅阻证的治疗效果,探讨其防治本病的机理。
方法：采用随机对照的研究方法,将符合糖耐量减低合并脂代谢紊乱气阴两虚,痰瘀壅阻证诊断标准的患者60例,随机分为治疗组和对照组各30例。在生活方式干预和西药常规治疗的基础上,治疗组加用中药。3个月为一个疗程。治疗前后两组分别评价其临床症状、体征的变化,治疗前后血糖、糖化血红蛋白、体重、体重指数、腰围、臀围、腰臀比、胰岛素、胰岛素敏感指数、血脂指标,以及安全性指标。全部数据以SPSS15.0统计软件进行统计学分析。
结果：治疗前两组的性别、年龄、病程等基线数据经统计学处理无显著性差异,有可比性(P>0.05)。①两组患者的中医证候积分治疗前后比较以及治疗后组间比较均有显著性差别。治疗组中医证候疗效总有效率达93.33%；对照组中医证候疗效有效率为50.00%。经统计学处理后治疗组显著优于对照组,具有统计学差异(P<0.01)。②肥胖相关指标方面,治疗后两组患者体重、BMI有所降低,与治疗前比较均有显著性差异(P<0.01)；治疗组体重改善较对照组有显著性差异(P<0.01),治疗组BMI改善较对照组有差异(P<0.05)；两组治疗后腰围、臀围、腰臀比与治疗前比较：治疗组的腰围和腰臀比均有显著性差异(P<0.01),治疗组在臀围及对照组在腰围、臀围、腰臀比方面无明显差异(P>0.05),治疗后治疗组与对照组腰围、腰臀比比较有差异(P<0.05)。③两组患者治疗后空腹血糖、餐后2小时血糖、糖化血红蛋白均明显降低,与治疗前比较均有显著性差异(P<0.01)；治疗组空腹血糖、餐后2小时血糖、糖化血红蛋白改善较对照组有显著性差异(P<0.01)。降糖效果分析,治疗组总有效率90.00%,对照组26.67%,治疗组总有效率优于对照组(P<0.01)。④治疗后治疗组患者空腹胰岛素有所降低、IAI指数有所升高,与治疗前比较均有显著性差异(P<0.01)；治疗前后对照组空腹胰岛素比较无明显差异(P>0.05),治疗后对照组IAI有所升高,与治疗前比较有差异(P<0.05)。治疗组空腹胰岛素、IAI的改善较对照组均有显著性差异(P<0.01)。⑤血脂指标方面,治疗组和对照组患者治疗后TG、TC、LDL-C水平下降,HDL-C水平升高,与治疗前比较均有显著性差异(P<0.01)。组间比较治疗组TG、TC、HDL-C水平改善均较对照组具有显著性差异(P<0.01),LDL-C水平改善均较对照组具有差异(P<0.05)。血脂疗效分析,治疗组总有效率93.33%,对照组33.33%,治疗组总有效率优于对照组(P<0.01)。⑥安全性指标：肝肾功能检查均在正常范围。两组均未见严重的不良反应。
结论：从初步临床研究来看,糖脂清方治疗效果优于单纯西药治疗,中药治疗可改善糖耐量减低合并脂代谢紊乱患者的临床症状,改善肥胖相关指标,降低血糖、糖化血红蛋白,降低胰岛素,增加胰岛素敏感性,调节血脂,且安全、有效,具有广泛的应用前景,值得进一步深入研究。
Purpose:To discuss the understanding of traditional Chinese medicine about impaired glucose tolarence combined with dyslipidemia by using prescription of tangzhiqing. To observe the therapeutic efficacy of this method in treating the syndrome of deficiency of both Qi and Yin with phlegm and blood stasis of impaired glucose tolarence combined with dyslipidemia and to investigate the mechanism of this method.
Methods:A randomized, controlled trial was conducted.60patients with the syndrome of deficiency of both Qi and Yin with phlegm and blood stasis of impaired glucose tolarence combined with dyslipidemia were randomly classified into two groups. Besides the intervention of living behavior and western medicine, the patients of the treatment group (n=30) were treated by Chinese medicine while the patients of control group (n=30) were not. Three months was a course of treatment. The observed indexes included both change in the clinical symptoms and signs, FBG, PBG, HbAlC, weight, BMI, WC, HC, WHR, FINS, IAI, blood-fat and safety indexes. All data were analyzed by the SPSS15.0statistics software.
Results:Before treatment, the gender, age, course of disease of the two groups had no differeces.①Both the treatment group and control group have significant difference on curative effect score between before and after treatment and the two groups. The total curative effect of treatment group was93.33%while total curative effect of control group was50,00%. The treatment group gained an advantage over the control group (P<0.01).②The weight, BMI of both groups and the WC, WHR of treatment group were decreased, compared with pre-treatment there is statistically significant (P<0.01). The WC, HC, WHR of control group and the HC of treatment group were not decreased after treatment(P>0.05). The descent of BMI, WC, WHR in treatment group had a statistically significant compared with control group(P<0.05). The treatment group had an advantage over the control group in weight(P<0.01).③The FBG, PBG, HbAlC of the two groups were decreased, compared with pre-treatment there is statistically significant (P<0.01). The total curative effect of treatment group is93.33%, which of control group is50.00%. And the treatment group had an advantage over the control group(P<0.01).④The FINS of the treatment group were decreased, the IAI were elevated, compared with pre-treatment there is statistically significant (P<0.01). The IAI of control group were elevated, compared with pre-treatment there is statistically significant (p<0.05) while the FINS didn't (P>0.05). And the treatment group had an advantage over the control group(P<0.01).⑤The TG, TC, LDL-C of the two groups were decreased, the HDL-C of them were elevated, compared with pre-treatment there is a remarkable statistically significant (P<0.01). And the treatment group had an advantage over the control group in TG, TC, HDL-C(P<0.01). The curative effect of blood fat in treatment group reached93.33%, which was33.33%in control group. The curative effect of treatment group was better than that of control group(p<0.01).⑥Safety indicators: Liver and kidney function tests were in the normal range. Both groups were no severe adverse reactions.
Conclusion:From the preliminary clinical research, the prescription of tangzhiqing can not only improve the clinical symptoms and insulin sensitivity, but also can reduce weight, blood glucose, lipid. It is safe and effective has a broad prospect of application. It is worth studying deeply and developing further.
方法：采用随机对照的研究方法,将符合糖耐量减低合并脂代谢紊乱气阴两虚,痰瘀壅阻证诊断标准的患者60例,随机分为治疗组和对照组各30例。在生活方式干预和西药常规治疗的基础上,治疗组加用中药。3个月为一个疗程。治疗前后两组分别评价其临床症状、体征的变化,治疗前后血糖、糖化血红蛋白、体重、体重指数、腰围、臀围、腰臀比、胰岛素、胰岛素敏感指数、血脂指标,以及安全性指标。全部数据以SPSS15.0统计软件进行统计学分析。
结果：治疗前两组的性别、年龄、病程等基线数据经统计学处理无显著性差异,有可比性(P>0.05)。①两组患者的中医证候积分治疗前后比较以及治疗后组间比较均有显著性差别。治疗组中医证候疗效总有效率达93.33%；对照组中医证候疗效有效率为50.00%。经统计学处理后治疗组显著优于对照组,具有统计学差异(P<0.01)。②肥胖相关指标方面,治疗后两组患者体重、BMI有所降低,与治疗前比较均有显著性差异(P<0.01)；治疗组体重改善较对照组有显著性差异(P<0.01),治疗组BMI改善较对照组有差异(P<0.05)；两组治疗后腰围、臀围、腰臀比与治疗前比较：治疗组的腰围和腰臀比均有显著性差异(P<0.01),治疗组在臀围及对照组在腰围、臀围、腰臀比方面无明显差异(P>0.05),治疗后治疗组与对照组腰围、腰臀比比较有差异(P<0.05)。③两组患者治疗后空腹血糖、餐后2小时血糖、糖化血红蛋白均明显降低,与治疗前比较均有显著性差异(P<0.01)；治疗组空腹血糖、餐后2小时血糖、糖化血红蛋白改善较对照组有显著性差异(P<0.01)。降糖效果分析,治疗组总有效率90.00%,对照组26.67%,治疗组总有效率优于对照组(P<0.01)。④治疗后治疗组患者空腹胰岛素有所降低、IAI指数有所升高,与治疗前比较均有显著性差异(P<0.01)；治疗前后对照组空腹胰岛素比较无明显差异(P>0.05),治疗后对照组IAI有所升高,与治疗前比较有差异(P<0.05)。治疗组空腹胰岛素、IAI的改善较对照组均有显著性差异(P<0.01)。⑤血脂指标方面,治疗组和对照组患者治疗后TG、TC、LDL-C水平下降,HDL-C水平升高,与治疗前比较均有显著性差异(P<0.01)。组间比较治疗组TG、TC、HDL-C水平改善均较对照组具有显著性差异(P<0.01),LDL-C水平改善均较对照组具有差异(P<0.05)。血脂疗效分析,治疗组总有效率93.33%,对照组33.33%,治疗组总有效率优于对照组(P<0.01)。⑥安全性指标：肝肾功能检查均在正常范围。两组均未见严重的不良反应。
结论：从初步临床研究来看,糖脂清方治疗效果优于单纯西药治疗,中药治疗可改善糖耐量减低合并脂代谢紊乱患者的临床症状,改善肥胖相关指标,降低血糖、糖化血红蛋白,降低胰岛素,增加胰岛素敏感性,调节血脂,且安全、有效,具有广泛的应用前景,值得进一步深入研究。
Purpose:To discuss the understanding of traditional Chinese medicine about impaired glucose tolarence combined with dyslipidemia by using prescription of tangzhiqing. To observe the therapeutic efficacy of this method in treating the syndrome of deficiency of both Qi and Yin with phlegm and blood stasis of impaired glucose tolarence combined with dyslipidemia and to investigate the mechanism of this method.
Methods:A randomized, controlled trial was conducted.60patients with the syndrome of deficiency of both Qi and Yin with phlegm and blood stasis of impaired glucose tolarence combined with dyslipidemia were randomly classified into two groups. Besides the intervention of living behavior and western medicine, the patients of the treatment group (n=30) were treated by Chinese medicine while the patients of control group (n=30) were not. Three months was a course of treatment. The observed indexes included both change in the clinical symptoms and signs, FBG, PBG, HbAlC, weight, BMI, WC, HC, WHR, FINS, IAI, blood-fat and safety indexes. All data were analyzed by the SPSS15.0statistics software.
Results:Before treatment, the gender, age, course of disease of the two groups had no differeces.①Both the treatment group and control group have significant difference on curative effect score between before and after treatment and the two groups. The total curative effect of treatment group was93.33%while total curative effect of control group was50,00%. The treatment group gained an advantage over the control group (P<0.01).②The weight, BMI of both groups and the WC, WHR of treatment group were decreased, compared with pre-treatment there is statistically significant (P<0.01). The WC, HC, WHR of control group and the HC of treatment group were not decreased after treatment(P>0.05). The descent of BMI, WC, WHR in treatment group had a statistically significant compared with control group(P<0.05). The treatment group had an advantage over the control group in weight(P<0.01).③The FBG, PBG, HbAlC of the two groups were decreased, compared with pre-treatment there is statistically significant (P<0.01). The total curative effect of treatment group is93.33%, which of control group is50.00%. And the treatment group had an advantage over the control group(P<0.01).④The FINS of the treatment group were decreased, the IAI were elevated, compared with pre-treatment there is statistically significant (P<0.01). The IAI of control group were elevated, compared with pre-treatment there is statistically significant (p<0.05) while the FINS didn't (P>0.05). And the treatment group had an advantage over the control group(P<0.01).⑤The TG, TC, LDL-C of the two groups were decreased, the HDL-C of them were elevated, compared with pre-treatment there is a remarkable statistically significant (P<0.01). And the treatment group had an advantage over the control group in TG, TC, HDL-C(P<0.01). The curative effect of blood fat in treatment group reached93.33%, which was33.33%in control group. The curative effect of treatment group was better than that of control group(p<0.01).⑥Safety indicators: Liver and kidney function tests were in the normal range. Both groups were no severe adverse reactions.
Conclusion:From the preliminary clinical research, the prescription of tangzhiqing can not only improve the clinical symptoms and insulin sensitivity, but also can reduce weight, blood glucose, lipid. It is safe and effective has a broad prospect of application. It is worth studying deeply and developing further.
引文
[1]张英健.2-型糖尿病探索中的预防性药物干预治疗[J].实用糖尿病杂志，1999,1(3)：13.
[2]Albert KG. Clinical Care/Education/Nutrition[J].Diabet Care,1996,13(11):927-937.
[3]Unmin N, shaw J, ZimmetP.糖耐量低减和空腹血糖受损定义及干预的现状[J].中华内分泌代谢杂志，2003.19(1)：附录1-8.
[4]Tominaga M. Nippon Rinsho,1996,54(10):2643-2648.
[5]Harris MI. Diabet Med,1996,13(3 suppl2):9-11.
[6]Dowse GK. Med J Aust.1994,160(12):767-774.
[7]全国糖尿病防治协作组[J].中华内科杂志.1997,6：180-185.
[8]Lillioja M et al.[J]. N Engl J Med,1988,318:1217.
[9]Haffner SM et al.[J].Diabetes,1996,45:742.
[10]Haffner SM et al.[J].Diabet Care,1996,9:67.
[11]Matsmoto K et al.[J].Diabet Care,1997.20:1562.
[12]贾伟平.中国人糖耐量异常与胰岛素抵抗和胰岛素分泌[J].中国糖尿病杂志,2000，8(2)：67-71.
[13]朱敏、方京冲.不同阶段糖尿病p细胞功能和胰岛素抵抗及其相关因素分析[J].复旦学报(医学版)2006.5(3).33.
[14]廖二元.莫朝晖.内分泌学[M].下册.第2版.北京：人民卫生出版社：1354-1418.
[15]Fuller JII,Ship MJ.Roes G,et al. Mortality from coronary heart disease and stroke in relation to degree of glycemia the White hall study.[J]. Br Med J,1983,278(7):867-870.
[16]傅茂，傅祖植,糖耐量递减的危害及其机制[J].中华内分泌代谢杂志,1989,5(1)：20-22.
[17]潘孝仁,李光伟,刚勇等.糖耐量低减的特征及其与冠心病的关联[J].中华内分泌代谢杂志,1989,5(1)：20-22.
[18]COHEN J A, JEFFERS B W, FALDUT D,et al. Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non insulin dependent diabetes mellitus (NIDDM) [J]. Muscle Nerve,1998,21:72-80.
[19]SUMNER C J, SHETHS, GRIFINJW.et al.The spectrum of neuropathy in diabetes and impaired glucose tolerance[J]. Neurol,2003,60:108-111.
[20]时乐,黎蕾.糖尿病血管并发症线粒体氧化损伤机制及药物治疗进展[J].中华老年医学杂志,2006,25：228-231.
[21]钱荣立.高度重视IGT糖尿病遏制在萌芽状态[J].国际糖尿病联盟西太区大会特刊资料,2002.
[22]DECODE Study Group. Glucose tolerance and cardiovascular mortality:comparison of fasting and2-hour diagnostic criteria[J].Arch Intern Med,2001,161:397-405.
[23]胡晖.杨希立.李健民,等.冠心病患者血脂异常与胰岛素抵抗的关系[J].中国现代医学杂志，2002，12(10)：65-66.
[24]Christian W, Clifton B, Richard Ep. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance[J].Diabetes,1999,48(11):2197-2201.
[25]张昌玉,李太华,马先宪,等.糖耐量减退及空腹血糖异常患者血清载脂蛋白B、A1检测及其临床意义[J].临床内科杂志,2002,19(1)：41-43.
[26]Haag M, Dippenaar N G. Dietary fats, fatty acids and insulin resistance:Short review of a multifaceted connection[J]. Med Sci Monit,2005,11(12):359-367.
[27]王岚,卢明瑜,任景怡,等.高脂血症患者不同血脂异常分型与糖代谢的相关性研究[J]北京大学学报(医学版).2011,43(3)：427-431.
[28]杨光.辨证治疗糖尿病并高脂血症临床分析[J].中国中医急症2009,1(18)：1.
[29]杨泽,郑宏,史晓红,等.超重、肥胖及其与糖尿病的患病风险分析[J].中华内分泌代谢杂志,2003,19(6)：177-180.
[30]邢小燕.肥胖和胰岛素抵抗综合征[J].中国临床医生,2003,31(3)：5.
[31]Eviksson KF, Lindgarde F. Prevention of NIDDM by diet and physical exercise. The six-year Malmo feasibility[J].Diabetologia,1991,34(8):891-898.
[32]The Diabetes Prevention Program (DPP) Research group. The Diabetes Prevention Program (DPP): deseription of lifestyle intervention[J].Diabetes Care,2002,25:2165-2171.
[33]Meigs JB, Natham DM, D'Agostino RB Sr, et al. Fasting and postchalllenye Glycemia and Cardiovascular disease risk the framingham off spring Study[J].Diabetes Care.2002,25(10):1845-1850.
[34]Singleton JR, Smith AC, Russell JW, et al. Microvascular complications of impaired glucose tolerance[J].Diabetes,2003,52(12):2867-2873.
[35]Chiasson JL, Josse RG, Gomis R, et al. Acarhose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randlomised trial[J].Lancet,2002 Jun 15:359(9323):2072-2077.
[36]Saloranta C, Guitard C, Peeher E, et al. Nateglinide improves early insulin secretion and controls post prandial glucose excursions in a prediabetic population[J].Diabetes Care,2002 Dec,25(12):2141-2146.
[37]张凤平.行为和药物干预治疗糖耐量低减疗效比较[J].实用糖尿病杂志,2006,3(4)：15-16.
[38]吕仁和.糖尿病及其并发症中西医结合诊治学[M].北京：人民卫生出版社,1997,1：29.
[39]钱为明.糖尿病中西医学概论[M].北京：中国科学技术出版社,2003,52.
[40]姬厚民.七味白术散加甘草芍药汤治疗葡萄糖耐量减低患者31例[J].中原医刊,2007,34(5)：24-26.
[41]陈刚.健脾逆瘅汤治疗糖耐量减低48例[J].四川中医,2001,19(11)：43.
[42]颜爱群.从脾论治糖耐量低减的疗效观察[J].国际医药卫生导报,2006,12(16)：63.
[43]陈弼沧,吴秋英,王丽英,杨叔禹运用补脾益气法治疗糖尿病经验[J].辽宁中医杂志,2005,32(4)：269-270.
[44]周卓宁.自拟花芪降糖方干预糖耐量异常疗效观察[J].广西中医药,2001,24(6)：13-15.
[45]韩瑞英,韩瑞卿.糖肾康对糖耐量异常15例治疗观察[J].安徽中医学院学报,1999,18(3)：21-22.
[46]黄淑玲,麦敏.消瘅汤逆转糖耐量低减的临床研究[J].中国中医药科技,2005,12(2)：7.
[47]王凤荣,郑娴,毛丹,高脂血症以痰瘀论治[J].中华中医药学刊,2007,25(4)：669-670.
[48]杨俐,陈学忠,尹方.高脂血症痰浊病机探讨[J].中医药临床杂志,2005,17(6)：539-540.
[49]王帅.从肝论治高脂血症探要[J].实用中医内科杂志,2008,22(9)：40-41.
[50]肖艳皎,刘延祥.试析高脂血症从脾论治[J].甘肃科技纵横,2007,36(4)：194.
[51]尹方，陈学忠,杨俐.从肾虚血瘀辨治高脂血症[J].四川中医.2006，24(1)：25-26.
[52]王振华,雷燕.从病证互参角度对高脂血症基本病机的思考[J].中国中医药信息杂志,2007,14(6)：84-85.
[53]陆源源,陈文霞.糖耐量低减者胰岛素水平与中医辨证分型关系[J].浙江中医杂志.2003.38(5)：220.
[54]连健儿.辨证分型治疗葡萄糖耐量低减60例[J].浙江中医杂志，.2004,12(1)：521.
[55]陈路燕.糖耐量低减的中医辨证分型[J].中国中医基础医学杂志,2007,13(3)：223-224.
[56]罗广波.不同体质的糖调节受损患者与胰岛素抵抗相关性研究[J].新中医,2008,40(9)：44-45.
[57]陈济民,潘秀群.中药治疗糖耐量低减72例疗效观察[J].浙江中医药大学学报.2006,30(6)：652-653.
[58]陈济民,潘秀群,王琴素.玉液汤加减治疗糖耐量低减的临床观察[J].湖北中医学院学报,2006,8(2)：55.
[59]周祥兰,孙延,,王行.参芪降糖颗粒对糖耐量减低者干预治疗及胰岛p细胞功能评价[J].中国中医急症,2006,15(4)：369-370.
[60]孟凤仙.降糖消脂饮对34例IGT者糖脂代谢的影响[J].中国中医药信息杂志，,2000,7(8)：31-32.
[61]曾永红,陈凡，王育珊等.中西医结合防治糖耐量异常及轻型糖尿病疗效观察[J].中国中西医结合脾胃杂志,2000,8(4)：196-198.
[62]姜国良,申国明,周萍.三黄脂消饮改善糖耐量减低患者胰岛功能的临床研究.齐齐哈尔医学院学报[，J].2007，28(21)：2573-2574.
[63]韩崇伟.健脾化痰治疗高脂血症的理论探讨[J].山东医药,2006,46(10)：78.
[64]赵州凤.辨证治疗高脂血症80例[J].陕西中医,2007,28(11)：1500-1501.
[65]尚留选.健脾化痰通络法治疗高脂血症154例临床体会[J].光明中医,2008,23(6)：763-764.
[66]何水勇,魏晓.魏品康治疗高脂血症的经验[J].湖北中医杂志,2004,26(10)：19.
[67]吴燕.中医辨证合苯扎贝特治疗高脂血症56例[J].河南中医,2006,26(9)：27-28.
[68]张万祥,林竹.中医药治疗高血脂研究进展[J].甘肃中医,2006,19(12)：47-49.
[69]顾翔华.高脂血症的中医药研究进展[J].湖北中医杂志,2010,32(9)：76-78.
[70]徐晓莉.针灸治疗高脂血症的研究进展[J].光明中医,2010,25(2)：325-327.
[71]李芳,农艳.针灸治疗高脂血症的研究概述[J].江西中医学院学报,2010,22(4)：87-91.
[72]黄健琳,辜孔进.温针灸治疗高脂血症之探讨[J].中医药导报,2010,16(9)：81-82.
[73].王凌云，毛红蓉.穴位埋线治疗高脂血症[J].中国康复.2009.24(2)：123.
[74]赵荣.针罐配合刺络放血治疗高脂血症20例[J].上海针灸杂志,2010,，29(10)：652-653.
[75]黄华超.艾炷灸治疗高脂血症65例[J].实用中医药杂志,2010,26(7)：494-495.
[76]毛红蓉,徐浩.复方当归注射液注射丰隆穴治疗高脂血症的临床研究[J].湖北中医杂志,2007,29(10)：15-16.
[77]姚斐，赵毅,李文涛.一指禅推拿治疗高脂血症的临床疗效观察[J].中华中医药学会推拿分会第九届推拿学术年会暨浙江省中医药学会推拿分会继续教育项目论文汇编.2006年
[78]中国成人血脂异常防治指南[J].中华心血管病杂志,2007,(5)：390-419.
[79]郑筱萸,中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002：227.
[80]中华中医药学会.糖尿病中医防治指南[M].北京：中国中医药出版社,2007：12.
[81]潘长玉,陆菊明,田慧等.首都钢铁公司成年人糖尿病患病率的调查[J].中华医学杂志,1997,7(5)：409.
[82]Knolvler WC. Barrett-ConnorE, Fowler SE. et al.The Diabetes Prevention Program (DPP):reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin[J].N Engl J Med,2002:346,393-403.
[83]夏伦祝,徐先祥,张睿.太子参多糖对糖尿病大鼠糖、脂代谢的影响[J].中国药业,2009,18(9)：17.
[84]倪受东,夏伦祝,徐先祥,等.太子参多糖对四氧嘧啶糖尿病小鼠的治疗作用[J].安徽医药,2010,14(5)：521.
[85]臧其中,何光星,郑振源,等.虫草多糖的药理作用[J].中草药,1985,16(7)：18.
[86]徐宝林,孙健,杨锋,等.补益药对细胞免疫功能影响的实验研究[J].浙江中医杂志,1996,31(5)：219-220.
[87]王家葵,郑军,沈映君,等.太子参总提取物对环磷酰胺处理动物免疫功能和胸腺、脾脏核酸含量的影响[J].中药药理与临床,1996,12(6)：16-18.
[88]徐宝林,孙健,杨锋,等.补益药对细胞免疫功能影响的实验研究[J].浙江中医杂志,1996,(5)：219-220.
[89]王玉玺,刘训红,李汉宝,等.太子参补益作用机理的探讨[J].南京部队医药,1992,(5)：21-22.
[90]钱汝红,丁铺发,宋宇红.首乌对大鼠外周淋巴细胞DNA损伤修复能力的影响[J].上海中医药杂志,1994,(4)：53.
[91]黄运忠.首乌提取液对小白鼠HDL中胆固醇含量的影响[J].右江民族医学院学报,1990.12(4)：8-9.
[92]李丽春,吴晓东,田维熙.何首乌提取物对脂肪酸合酶的抑制作用[J].中国生物化学与分子生物学报,2003,19(3)：297-304.
[93]姚鸣春,罗碧如,兰开蔚,等.中药何首乌抗衰老作用的研究[J].药学通报,1984,19(11)：28.
[94]王巍,王振华,石体仁,等.何首乌对老年鹌鹑寿命脂质代谢的影响[J].中西医结合杂志,1988,8(4)：223.
[95]姚鸣春.何首乌、柴胡对小鼠胸腺、肾上腺以及超氧化物歧化酶和血清蛋白的影响[J].成都中医学院学报,1983,(4)：49.
[96]陈可冀.抗衰老中药学[M].北京：中医古籍出版社,1989.309.
[97]彭延古,葛金文,邓奕辉.僵蚕抗凝血活性初步研究[J].湖南中医学院学报,2000,20(4)：18-19.
[98]彭延古.僵蚕抗实验性静脉血栓及作用机理的研究[J].血栓与止血,2001,7(3)：104-105.
[99]刘玉梅,相翠玉.鬼箭羽临床应用[J].中国医药导报,2007,4(21)：3-4.
[100]夏卫军,程海波,张莉.鬼箭羽治疗2型糖尿病实验研究[J].陕西中医,2001,22(8)：505.
[101]郎素梅,朱丹妮,等.中药鬼箭羽降糖有效部位的药效学和化学研究[J].中国药科大学学报,2003,34(2)：128-131.
[102]刘健美,徐宏举.化瘀降糖片治疗2型糖尿病及对血糖血流变的影响[J].陕西中医,2008,29(12)：1613-1615.
[103]李玉杰,来媛媛,王谦,等.鬼箭羽不同提取部位对糖尿病大鼠药理作用的研究[J].北京中医药大学学报,2010,33(3)：179-182.
[104]王巍,王晋华,赵德忠,等.活血化瘀药调脂作用的研究[J].中西医结合杂志,1988,(10)：62.
[105]尚文斌,程海波.唐含艳.鬼箭羽对糖尿病小鼠血糖及全血粘度的影响[J].南京中医药大学学报(自然科学版)，2000,16(3)：166-167.
[106]王萍.鬼箭羽抗心肌缺血作用及化学成分研究[D].黑龙江中医药大学：黑龙江中医药大学,2004：73-74.
[107]彭利,鲍宜桂，李忠业.复方鬼箭羽汤改善高血压病胰岛素抵抗和微循环的临床研究[J].陕西中医,2007(6)：677-679.
[108]Zhao R, Li Q, Xiao B. Effect ofLycium barbarum polysaccharide on the improvement of insulin resistance in NIDDM rats[J].Yakugaku Zasshi,2005,125(12):981-988.
[109]Luo Q, Cai Y, Yan J. Hypoglycemic and hypolipidemic effects and antioxidant activity of fruit extracts fromLycium barbarum [J].Life Sci,2004,76(2):137-149.
[110]杨新波，黄正明,曹文斌，等.枸杞多糖对正常小白鼠及四氧嘧啶致高血糖的影响[J].人民医药学专刊.1998,14(1)：11-13.
[111]黄正明,杨新波，曹文斌，等.枸杞多糖对小鼠链佐星性胰岛损伤及血糖的影响[J].世界华人消化杂志，2001,9(12)：1419-1421.
[113]Aggarwal,SGupta S.Increased apoptosis of Tcell subsets in aging humans:altered expression of Fas(CD95) FasLigandBci-2 and Bax[J].J Immunol,1998.160(4):1627.
[113]沈自尹,郭为民,陈瑜.枸杞多糖调控老年大鼠T细胞凋亡及相关基因表达的研究[J].中国免疫学杂志.2002,18(9)：628-630.
[114]汪积慧,李鸿梅.枸杞多糖免疫调节作用的研究[J].齐齐哈尔医学院学报,2002,23(11)：1204.
[115]田庚元.枸杞子糖缀合物的结构与生物活性研究[J].世界科学技术-中医药现代化.2003，.5(4)：22-30.
[116]马兰军,李峰,李波.决明子对肥胖大学生部分形态和生理指标干预效果的实验研究[J].时珍国医国药,2009,20(J)：41-43.
[117]沈奇桂,朱寿民.决明子对实验性高胆固醇血症和动脉粥样硬化的抑制作用及其机理探讨[J].浙江医科大学学报，1993，22(6)：246.
[118]刘菊秀,苗戎，狄俊英.决明子降压作用的实验研究[J].天津中医,1990(5)：37-38.
[119]龚建锋,俞明义.天花粉研究进展[J].浙江中西医结合杂志,2008,18(4)：263-264.
[120]王保龙,周芸,江阳,等.不同小鼠品系对天花粉蛋白诱导免疫抑制易感性的差异[J].现代免疫学,2004,24(3)：190-193.
[121]王威,三浦俊宏,史红等.复方中药糖脂清对KK-Ay小鼠糖脂代谢影响的机制探讨[J]天津中医药.2008,,25(3)：223-224.
[122]Yoshii H, Lam TKT, Gupta N. et al. Portal delivery of free fatty acids compared to peripheral delivery has no greater effect on hepatic glucose production but results in greater peripheral hyperinsulinemie[J]. Diabetes,2000,49(1):22-24.
[123]李玉红,张德芹,李晓新等.糖脂清对2型糖尿病大鼠氧化应激的影响[J]时珍国医国药2011.21(11)：2739-2740.
[124]柳占彪,李玉红,张少卓,等.糖脂清对高脂血症家兔糖脂代谢及肝组织的影响[J].中国实验方剂学杂志,2011,17(15)：135-138.
[2]Albert KG. Clinical Care/Education/Nutrition[J].Diabet Care,1996,13(11):927-937.
[3]Unmin N, shaw J, ZimmetP.糖耐量低减和空腹血糖受损定义及干预的现状[J].中华内分泌代谢杂志，2003.19(1)：附录1-8.
[4]Tominaga M. Nippon Rinsho,1996,54(10):2643-2648.
[5]Harris MI. Diabet Med,1996,13(3 suppl2):9-11.
[6]Dowse GK. Med J Aust.1994,160(12):767-774.
[7]全国糖尿病防治协作组[J].中华内科杂志.1997,6：180-185.
[8]Lillioja M et al.[J]. N Engl J Med,1988,318:1217.
[9]Haffner SM et al.[J].Diabetes,1996,45:742.
[10]Haffner SM et al.[J].Diabet Care,1996,9:67.
[11]Matsmoto K et al.[J].Diabet Care,1997.20:1562.
[12]贾伟平.中国人糖耐量异常与胰岛素抵抗和胰岛素分泌[J].中国糖尿病杂志,2000，8(2)：67-71.
[13]朱敏、方京冲.不同阶段糖尿病p细胞功能和胰岛素抵抗及其相关因素分析[J].复旦学报(医学版)2006.5(3).33.
[14]廖二元.莫朝晖.内分泌学[M].下册.第2版.北京：人民卫生出版社：1354-1418.
[15]Fuller JII,Ship MJ.Roes G,et al. Mortality from coronary heart disease and stroke in relation to degree of glycemia the White hall study.[J]. Br Med J,1983,278(7):867-870.
[16]傅茂，傅祖植,糖耐量递减的危害及其机制[J].中华内分泌代谢杂志,1989,5(1)：20-22.
[17]潘孝仁,李光伟,刚勇等.糖耐量低减的特征及其与冠心病的关联[J].中华内分泌代谢杂志,1989,5(1)：20-22.
[18]COHEN J A, JEFFERS B W, FALDUT D,et al. Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non insulin dependent diabetes mellitus (NIDDM) [J]. Muscle Nerve,1998,21:72-80.
[19]SUMNER C J, SHETHS, GRIFINJW.et al.The spectrum of neuropathy in diabetes and impaired glucose tolerance[J]. Neurol,2003,60:108-111.
[20]时乐,黎蕾.糖尿病血管并发症线粒体氧化损伤机制及药物治疗进展[J].中华老年医学杂志,2006,25：228-231.
[21]钱荣立.高度重视IGT糖尿病遏制在萌芽状态[J].国际糖尿病联盟西太区大会特刊资料,2002.
[22]DECODE Study Group. Glucose tolerance and cardiovascular mortality:comparison of fasting and2-hour diagnostic criteria[J].Arch Intern Med,2001,161:397-405.
[23]胡晖.杨希立.李健民,等.冠心病患者血脂异常与胰岛素抵抗的关系[J].中国现代医学杂志，2002，12(10)：65-66.
[24]Christian W, Clifton B, Richard Ep. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance[J].Diabetes,1999,48(11):2197-2201.
[25]张昌玉,李太华,马先宪,等.糖耐量减退及空腹血糖异常患者血清载脂蛋白B、A1检测及其临床意义[J].临床内科杂志,2002,19(1)：41-43.
[26]Haag M, Dippenaar N G. Dietary fats, fatty acids and insulin resistance:Short review of a multifaceted connection[J]. Med Sci Monit,2005,11(12):359-367.
[27]王岚,卢明瑜,任景怡,等.高脂血症患者不同血脂异常分型与糖代谢的相关性研究[J]北京大学学报(医学版).2011,43(3)：427-431.
[28]杨光.辨证治疗糖尿病并高脂血症临床分析[J].中国中医急症2009,1(18)：1.
[29]杨泽,郑宏,史晓红,等.超重、肥胖及其与糖尿病的患病风险分析[J].中华内分泌代谢杂志,2003,19(6)：177-180.
[30]邢小燕.肥胖和胰岛素抵抗综合征[J].中国临床医生,2003,31(3)：5.
[31]Eviksson KF, Lindgarde F. Prevention of NIDDM by diet and physical exercise. The six-year Malmo feasibility[J].Diabetologia,1991,34(8):891-898.
[32]The Diabetes Prevention Program (DPP) Research group. The Diabetes Prevention Program (DPP): deseription of lifestyle intervention[J].Diabetes Care,2002,25:2165-2171.
[33]Meigs JB, Natham DM, D'Agostino RB Sr, et al. Fasting and postchalllenye Glycemia and Cardiovascular disease risk the framingham off spring Study[J].Diabetes Care.2002,25(10):1845-1850.
[34]Singleton JR, Smith AC, Russell JW, et al. Microvascular complications of impaired glucose tolerance[J].Diabetes,2003,52(12):2867-2873.
[35]Chiasson JL, Josse RG, Gomis R, et al. Acarhose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randlomised trial[J].Lancet,2002 Jun 15:359(9323):2072-2077.
[36]Saloranta C, Guitard C, Peeher E, et al. Nateglinide improves early insulin secretion and controls post prandial glucose excursions in a prediabetic population[J].Diabetes Care,2002 Dec,25(12):2141-2146.
[37]张凤平.行为和药物干预治疗糖耐量低减疗效比较[J].实用糖尿病杂志,2006,3(4)：15-16.
[38]吕仁和.糖尿病及其并发症中西医结合诊治学[M].北京：人民卫生出版社,1997,1：29.
[39]钱为明.糖尿病中西医学概论[M].北京：中国科学技术出版社,2003,52.
[40]姬厚民.七味白术散加甘草芍药汤治疗葡萄糖耐量减低患者31例[J].中原医刊,2007,34(5)：24-26.
[41]陈刚.健脾逆瘅汤治疗糖耐量减低48例[J].四川中医,2001,19(11)：43.
[42]颜爱群.从脾论治糖耐量低减的疗效观察[J].国际医药卫生导报,2006,12(16)：63.
[43]陈弼沧,吴秋英,王丽英,杨叔禹运用补脾益气法治疗糖尿病经验[J].辽宁中医杂志,2005,32(4)：269-270.
[44]周卓宁.自拟花芪降糖方干预糖耐量异常疗效观察[J].广西中医药,2001,24(6)：13-15.
[45]韩瑞英,韩瑞卿.糖肾康对糖耐量异常15例治疗观察[J].安徽中医学院学报,1999,18(3)：21-22.
[46]黄淑玲,麦敏.消瘅汤逆转糖耐量低减的临床研究[J].中国中医药科技,2005,12(2)：7.
[47]王凤荣,郑娴,毛丹,高脂血症以痰瘀论治[J].中华中医药学刊,2007,25(4)：669-670.
[48]杨俐,陈学忠,尹方.高脂血症痰浊病机探讨[J].中医药临床杂志,2005,17(6)：539-540.
[49]王帅.从肝论治高脂血症探要[J].实用中医内科杂志,2008,22(9)：40-41.
[50]肖艳皎,刘延祥.试析高脂血症从脾论治[J].甘肃科技纵横,2007,36(4)：194.
[51]尹方，陈学忠,杨俐.从肾虚血瘀辨治高脂血症[J].四川中医.2006，24(1)：25-26.
[52]王振华,雷燕.从病证互参角度对高脂血症基本病机的思考[J].中国中医药信息杂志,2007,14(6)：84-85.
[53]陆源源,陈文霞.糖耐量低减者胰岛素水平与中医辨证分型关系[J].浙江中医杂志.2003.38(5)：220.
[54]连健儿.辨证分型治疗葡萄糖耐量低减60例[J].浙江中医杂志，.2004,12(1)：521.
[55]陈路燕.糖耐量低减的中医辨证分型[J].中国中医基础医学杂志,2007,13(3)：223-224.
[56]罗广波.不同体质的糖调节受损患者与胰岛素抵抗相关性研究[J].新中医,2008,40(9)：44-45.
[57]陈济民,潘秀群.中药治疗糖耐量低减72例疗效观察[J].浙江中医药大学学报.2006,30(6)：652-653.
[58]陈济民,潘秀群,王琴素.玉液汤加减治疗糖耐量低减的临床观察[J].湖北中医学院学报,2006,8(2)：55.
[59]周祥兰,孙延,,王行.参芪降糖颗粒对糖耐量减低者干预治疗及胰岛p细胞功能评价[J].中国中医急症,2006,15(4)：369-370.
[60]孟凤仙.降糖消脂饮对34例IGT者糖脂代谢的影响[J].中国中医药信息杂志，,2000,7(8)：31-32.
[61]曾永红,陈凡，王育珊等.中西医结合防治糖耐量异常及轻型糖尿病疗效观察[J].中国中西医结合脾胃杂志,2000,8(4)：196-198.
[62]姜国良,申国明,周萍.三黄脂消饮改善糖耐量减低患者胰岛功能的临床研究.齐齐哈尔医学院学报[，J].2007，28(21)：2573-2574.
[63]韩崇伟.健脾化痰治疗高脂血症的理论探讨[J].山东医药,2006,46(10)：78.
[64]赵州凤.辨证治疗高脂血症80例[J].陕西中医,2007,28(11)：1500-1501.
[65]尚留选.健脾化痰通络法治疗高脂血症154例临床体会[J].光明中医,2008,23(6)：763-764.
[66]何水勇,魏晓.魏品康治疗高脂血症的经验[J].湖北中医杂志,2004,26(10)：19.
[67]吴燕.中医辨证合苯扎贝特治疗高脂血症56例[J].河南中医,2006,26(9)：27-28.
[68]张万祥,林竹.中医药治疗高血脂研究进展[J].甘肃中医,2006,19(12)：47-49.
[69]顾翔华.高脂血症的中医药研究进展[J].湖北中医杂志,2010,32(9)：76-78.
[70]徐晓莉.针灸治疗高脂血症的研究进展[J].光明中医,2010,25(2)：325-327.
[71]李芳,农艳.针灸治疗高脂血症的研究概述[J].江西中医学院学报,2010,22(4)：87-91.
[72]黄健琳,辜孔进.温针灸治疗高脂血症之探讨[J].中医药导报,2010,16(9)：81-82.
[73].王凌云，毛红蓉.穴位埋线治疗高脂血症[J].中国康复.2009.24(2)：123.
[74]赵荣.针罐配合刺络放血治疗高脂血症20例[J].上海针灸杂志,2010,，29(10)：652-653.
[75]黄华超.艾炷灸治疗高脂血症65例[J].实用中医药杂志,2010,26(7)：494-495.
[76]毛红蓉,徐浩.复方当归注射液注射丰隆穴治疗高脂血症的临床研究[J].湖北中医杂志,2007,29(10)：15-16.
[77]姚斐，赵毅,李文涛.一指禅推拿治疗高脂血症的临床疗效观察[J].中华中医药学会推拿分会第九届推拿学术年会暨浙江省中医药学会推拿分会继续教育项目论文汇编.2006年
[78]中国成人血脂异常防治指南[J].中华心血管病杂志,2007,(5)：390-419.
[79]郑筱萸,中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002：227.
[80]中华中医药学会.糖尿病中医防治指南[M].北京：中国中医药出版社,2007：12.
[81]潘长玉,陆菊明,田慧等.首都钢铁公司成年人糖尿病患病率的调查[J].中华医学杂志,1997,7(5)：409.
[82]Knolvler WC. Barrett-ConnorE, Fowler SE. et al.The Diabetes Prevention Program (DPP):reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin[J].N Engl J Med,2002:346,393-403.
[83]夏伦祝,徐先祥,张睿.太子参多糖对糖尿病大鼠糖、脂代谢的影响[J].中国药业,2009,18(9)：17.
[84]倪受东,夏伦祝,徐先祥,等.太子参多糖对四氧嘧啶糖尿病小鼠的治疗作用[J].安徽医药,2010,14(5)：521.
[85]臧其中,何光星,郑振源,等.虫草多糖的药理作用[J].中草药,1985,16(7)：18.
[86]徐宝林,孙健,杨锋,等.补益药对细胞免疫功能影响的实验研究[J].浙江中医杂志,1996,31(5)：219-220.
[87]王家葵,郑军,沈映君,等.太子参总提取物对环磷酰胺处理动物免疫功能和胸腺、脾脏核酸含量的影响[J].中药药理与临床,1996,12(6)：16-18.
[88]徐宝林,孙健,杨锋,等.补益药对细胞免疫功能影响的实验研究[J].浙江中医杂志,1996,(5)：219-220.
[89]王玉玺,刘训红,李汉宝,等.太子参补益作用机理的探讨[J].南京部队医药,1992,(5)：21-22.
[90]钱汝红,丁铺发,宋宇红.首乌对大鼠外周淋巴细胞DNA损伤修复能力的影响[J].上海中医药杂志,1994,(4)：53.
[91]黄运忠.首乌提取液对小白鼠HDL中胆固醇含量的影响[J].右江民族医学院学报,1990.12(4)：8-9.
[92]李丽春,吴晓东,田维熙.何首乌提取物对脂肪酸合酶的抑制作用[J].中国生物化学与分子生物学报,2003,19(3)：297-304.
[93]姚鸣春,罗碧如,兰开蔚,等.中药何首乌抗衰老作用的研究[J].药学通报,1984,19(11)：28.
[94]王巍,王振华,石体仁,等.何首乌对老年鹌鹑寿命脂质代谢的影响[J].中西医结合杂志,1988,8(4)：223.
[95]姚鸣春.何首乌、柴胡对小鼠胸腺、肾上腺以及超氧化物歧化酶和血清蛋白的影响[J].成都中医学院学报,1983,(4)：49.
[96]陈可冀.抗衰老中药学[M].北京：中医古籍出版社,1989.309.
[97]彭延古,葛金文,邓奕辉.僵蚕抗凝血活性初步研究[J].湖南中医学院学报,2000,20(4)：18-19.
[98]彭延古.僵蚕抗实验性静脉血栓及作用机理的研究[J].血栓与止血,2001,7(3)：104-105.
[99]刘玉梅,相翠玉.鬼箭羽临床应用[J].中国医药导报,2007,4(21)：3-4.
[100]夏卫军,程海波,张莉.鬼箭羽治疗2型糖尿病实验研究[J].陕西中医,2001,22(8)：505.
[101]郎素梅,朱丹妮,等.中药鬼箭羽降糖有效部位的药效学和化学研究[J].中国药科大学学报,2003,34(2)：128-131.
[102]刘健美,徐宏举.化瘀降糖片治疗2型糖尿病及对血糖血流变的影响[J].陕西中医,2008,29(12)：1613-1615.
[103]李玉杰,来媛媛,王谦,等.鬼箭羽不同提取部位对糖尿病大鼠药理作用的研究[J].北京中医药大学学报,2010,33(3)：179-182.
[104]王巍,王晋华,赵德忠,等.活血化瘀药调脂作用的研究[J].中西医结合杂志,1988,(10)：62.
[105]尚文斌,程海波.唐含艳.鬼箭羽对糖尿病小鼠血糖及全血粘度的影响[J].南京中医药大学学报(自然科学版)，2000,16(3)：166-167.
[106]王萍.鬼箭羽抗心肌缺血作用及化学成分研究[D].黑龙江中医药大学：黑龙江中医药大学,2004：73-74.
[107]彭利,鲍宜桂，李忠业.复方鬼箭羽汤改善高血压病胰岛素抵抗和微循环的临床研究[J].陕西中医,2007(6)：677-679.
[108]Zhao R, Li Q, Xiao B. Effect ofLycium barbarum polysaccharide on the improvement of insulin resistance in NIDDM rats[J].Yakugaku Zasshi,2005,125(12):981-988.
[109]Luo Q, Cai Y, Yan J. Hypoglycemic and hypolipidemic effects and antioxidant activity of fruit extracts fromLycium barbarum [J].Life Sci,2004,76(2):137-149.
[110]杨新波，黄正明,曹文斌，等.枸杞多糖对正常小白鼠及四氧嘧啶致高血糖的影响[J].人民医药学专刊.1998,14(1)：11-13.
[111]黄正明,杨新波，曹文斌，等.枸杞多糖对小鼠链佐星性胰岛损伤及血糖的影响[J].世界华人消化杂志，2001,9(12)：1419-1421.
[113]Aggarwal,SGupta S.Increased apoptosis of Tcell subsets in aging humans:altered expression of Fas(CD95) FasLigandBci-2 and Bax[J].J Immunol,1998.160(4):1627.
[113]沈自尹,郭为民,陈瑜.枸杞多糖调控老年大鼠T细胞凋亡及相关基因表达的研究[J].中国免疫学杂志.2002,18(9)：628-630.
[114]汪积慧,李鸿梅.枸杞多糖免疫调节作用的研究[J].齐齐哈尔医学院学报,2002,23(11)：1204.
[115]田庚元.枸杞子糖缀合物的结构与生物活性研究[J].世界科学技术-中医药现代化.2003，.5(4)：22-30.
[116]马兰军,李峰,李波.决明子对肥胖大学生部分形态和生理指标干预效果的实验研究[J].时珍国医国药,2009,20(J)：41-43.
[117]沈奇桂,朱寿民.决明子对实验性高胆固醇血症和动脉粥样硬化的抑制作用及其机理探讨[J].浙江医科大学学报，1993，22(6)：246.
[118]刘菊秀,苗戎，狄俊英.决明子降压作用的实验研究[J].天津中医,1990(5)：37-38.
[119]龚建锋,俞明义.天花粉研究进展[J].浙江中西医结合杂志,2008,18(4)：263-264.
[120]王保龙,周芸,江阳,等.不同小鼠品系对天花粉蛋白诱导免疫抑制易感性的差异[J].现代免疫学,2004,24(3)：190-193.
[121]王威,三浦俊宏,史红等.复方中药糖脂清对KK-Ay小鼠糖脂代谢影响的机制探讨[J]天津中医药.2008,,25(3)：223-224.
[122]Yoshii H, Lam TKT, Gupta N. et al. Portal delivery of free fatty acids compared to peripheral delivery has no greater effect on hepatic glucose production but results in greater peripheral hyperinsulinemie[J]. Diabetes,2000,49(1):22-24.
[123]李玉红,张德芹,李晓新等.糖脂清对2型糖尿病大鼠氧化应激的影响[J]时珍国医国药2011.21(11)：2739-2740.
[124]柳占彪,李玉红,张少卓,等.糖脂清对高脂血症家兔糖脂代谢及肝组织的影响[J].中国实验方剂学杂志,2011,17(15)：135-138.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |